Treatment with Revatio (sildenafil) at a higher dose than the recommended and previously approved doses did not significantly increase mortality of adults with pulmonary arterial hypertension (PAH). That’s according to results from the Phase 3b/4 AFFILIATE trial (NCT02060487), which compared three treatment doses, each given three times…
News
Experts recommend taking Uptravi (selexipag) with food and slowly titrating it up, at a frequency of less than weekly or by raising one of the two daily doses, as tolerated, while caring for any side effects adults with pulmonary arterial hypertension (PAH) may be having. The recommendation came…
Chronic alcohol consumption damages the heart and blood vessels in ways that seem to set the stage for pulmonary arterial hypertension (PAH), according to a study in male rats. These findings “yield new insight into the adverse effect of ethanol on cardiopulmonary [heart and lung] health, providing a foundation…
Life support measures, specifically the need for assisted breathing, and elevated blood levels of bilirubin, a marker of liver damage, are among the factors that predict worse outcomes after a lung transplant in people with idiopathic pulmonary arterial hypertension (IPAH), a study reports. A new predictive model that includes…
Levels of fractional exhaled nitric oxide (FeNO) — a measure of how much nitric oxide a person exhales — may be used as a diagnostic tool for severe disease in people with idiopathic pulmonary arterial hypertension (iPAH), a study has found. Specifically, patients with FeNO levels lower than 23…
Pulmonary arterial hypertension (PAH) patients enrolled in a Phase 2b clinical trial testing AV-101, an inhaled formulation of imatinib, entered the trial with significant disease despite use of triple background therapy, according to data shared by developer Aerovate Therapeutics. The company said the study population will allow for…
AER-901, a new inhaled formulation of imatinib delivered via a specialized device, was predicted to reach 2-3 times higher levels in the lung tissue over standard inhalers among people with forms of pulmonary hypertension (PH), according to new data from Aerami Therapeutics, its developer. Having been proven to…
Findings of a new study into pericytes — cells with multiple functions including immune cell regulation — suggest that targeting a protein known as HIF-2alpha, which is involved in the response to low oxygen conditions, or hypoxia, may be a potential therapeutic approach for pulmonary arterial hypertension (PAH). The…
Researchers have identified two inflammation-related genes — SELE and CCL20 — whose activity could serve as diagnostic biomarkers for the development of pulmonary hypertension (PH) in people with COVID-19. Further, the team also identified molecules that target these biomarkers as possible therapeutic approaches for managing the complication. Overall, the…
Reduced exercise capacity appeared to be a consequence of cardiac and pulmonary changes, but not skeletal muscle alterations, in rat models of pulmonary hypertension (PH), according to recent research. While no functional problems with muscles could be observed despite obvious impairments in exercise capacity, significant cardiopulmonary dysfunction was already present.
The U.S. Food and Drug Administration (FDA) has supported Inhibikase Therapeutics’ Phase 2/3 trial of its experimental formulation of imatinib, called IkT-001Pro, for pulmonary arterial hypertension (PAH), the company reports. In a meeting, the FDA asked the company to complete a preclinical study in cells to compare…
A noninvasive intervention that makes use of ultrasound to target the splenic nerve — a nerve in the spleen, an organ in which immune cells develop — was found to reduce inflammation and the severity of pulmonary arterial hypertension (PAH) in rat models of the disease, according to a…
